AbCellera Biologics Inc (OQ:ABCL)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 2215 Yukon Street
Tel: N/A
IR: See website
Key People
Carl L. G. Hansen
Chief Executive Officer, Co-Founder, Director
Veronique Lecault
Co-Founder, Chief Operating Officer, Director
Kevin Heyries
Co-Founder, Head of Business Development
Andrew Booth
Chief Financial Officer
Ester Falconer
Chief Technology Officer
Tryn Stimart
Chief Compliance Officer, Company Secretary, Chief Legal Officer
Neil Aubuchon
Chief Commercial Officer
Neil Berkley
Chief Business Officer
Business Overview
AbCellera Biologics Inc. (AbCellera) is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.
Financial Overview
For the nine months ended 30 September 2021,AbCellera Biologics Inc revenues increased from $25.2M to$235.9M. Net income increased from $1.9M to $93.5M.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Net income benefited from Grants and incentives increase of19% to $12.2M (income). Basic Earnings per Share excludingExtraordinary Items increased from $0.01 to $0.35.
Employees: 206 as of Dec 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $2,137M as of Sep 30, 2021
Annual revenue (TTM): $443.80M as of Sep 30, 2021
EBITDA (TTM): $296.80M as of Sep 30, 2021
Net annual income (TTM): $210.52M as of Sep 30, 2021
Free cash flow (TTM): $212.05M as of Sep 30, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 281,581,275 as of Nov 8, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.